Back to Massachusetts

H1080 • 2025

An Act relative to copay assistance

An Act relative to copay assistance

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor
Ashe, Brian M.
Last action
2026-03-12
Official status
Accompanied a study order, see H5223
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

An Act relative to copay assistance

An Act relative to copay assistance By Representatives Ashe of Longmeadow and Puppolo of Springfield, a petition (accompanied by bill, House, No.

What This Bill Does

  • An Act relative to copay assistance By Representatives Ashe of Longmeadow and Puppolo of Springfield, a petition (accompanied by bill, House, No.
  • 1080) of Brian M.
  • Ashe and Angelo J.
  • Puppolo, Jr., relative to copay assistance for certain branded drugs.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-03-12 House

    Accompanied a study order, see H5223

  2. 2025-10-01 Joint

    Hearing rescheduled to 10/01/2025 from 10:30 AM-11:20 PM in B-1 and Virtual Hearing updated to New End Time

  3. 2025-10-01 Joint

    Hearing scheduled for 10/01/2025 from 10:30 AM-01:00 PM in B-1

  4. 2025-09-29 Joint

    Hearing rescheduled to 10/01/2025 from 10:30 AM-01:00 PM in B-1 and Virtual Hearing location changed

  5. 2025-09-25 Joint

    Hearing rescheduled to 10/01/2025 from 10:30 AM-01:00 PM in A-1 and Virtual Hearing location changed

  6. 2025-09-19 Joint

    Hearing scheduled for 10/01/2025 from 10:30 AM-01:00 PM in B-2

  7. 2025-02-27 House

    Referred to the committee on Financial Services

  8. 2025-02-27 Senate

    Senate concurred

Official Summary Text

An Act relative to copay assistance
By Representatives Ashe of Longmeadow and Puppolo of Springfield, a petition (accompanied by bill, House, No. 1080) of Brian M. Ashe and Angelo J. Puppolo, Jr., relative to copay assistance for certain branded drugs. Financial Services.

Current Bill Text

Read the full stored bill text
×

Bill H.1080

Chapter 175 is hereby amended by inserting after section 47ZZ, added by section 3 of chapter 231 of the acts of 2024, the following section:-

Section 47AAA. (a) For the purposes of this section, the following words shall, unless the context clearly requires otherwise, have the following meanings:

“Branded drug”, a drug sold or marketed under a specific name or trademark.

“Equivalent drug”, a drug that has been approved by the federal Food and Drug Administration as an AB rated generic therapeutic equivalent of a branded drug.

“FDA”, the federal Food and Drug Administration.

(b) A policy, contract, agreement, plan or certificate of insurance issued, delivered or renewed within or without the commonwealth shall not discontinue or reduce its coverage of a branded drug because the FDA has approved an equivalent drug until such equivalent drug has been available for use in the commonwealth for at least 3 calendar months, as determined by the department of public health.

(c) In making the determination that an equivalent drug is available for use in the commonwealth, the department of public health shall consider: (i) the number and geographic distribution of pharmacies that have the equivalent drug in stock; (ii) the supply level of the equivalent drug in the commonwealth and the incidence of the condition or illness for which the branded drug and equivalent drug are approved treatments; and (iii) any barriers patients may encounter to accessing the equivalent drug in the commonwealth.

(d) The department of public health may promulgate any regulations necessary to implement this section.

The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

Close